
I-Mab IMAB
Quarterly report 2025-Q2
added 03-21-2026
I-Mab P/S Ratio 2011-2026 | IMAB
Annual P/S Ratio I-Mab
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 94.1 | 4.1 | 0.386 | 0.255 | 1.04 | - | - | - | - | - | - |
All numbers in CNY currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 94.1 | 0.255 | 20 |
P/S Ratio of other stocks in the Biotechnology industry
| Issuer | P/S Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
1.75 | - | 2.43 % | $ 254 M | ||
|
Anika Therapeutics
ANIK
|
2.24 | $ 14.21 | -0.42 % | $ 208 M | ||
|
Aeterna Zentaris
AEZS
|
7.87 | - | 5.93 % | $ 314 M | ||
|
Albireo Pharma
ALBO
|
13.3 | - | -0.23 % | $ 916 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
5.53 | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
1.96 K | - | 2.54 % | $ 160 B | ||
|
Altimmune
ALT
|
7.76 K | $ 3.35 | -2.62 % | $ 295 M | ||
|
Ascendis Pharma A/S
ASND
|
947 | $ 216.26 | -0.83 % | $ 5 B | ||
|
Midatech Pharma plc
MTP
|
137 | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.39 K | - | -1.52 % | $ 24.7 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
1.73 | $ 19.12 | -0.57 % | $ 894 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
65.5 | - | - | $ 26.5 M | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
10.4 | $ 0.62 | 2.14 % | $ 7.1 M | ||
|
AgeX Therapeutics
AGE
|
0.099 | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
0.142 | - | -24.86 % | $ 820 K | ||
|
CRISPR Therapeutics AG
CRSP
|
1.25 K | $ 46.45 | -0.91 % | $ 4.18 B | ||
|
Acasti Pharma
ACST
|
0.203 | - | 4.01 % | $ 150 M | ||
|
Институт стволовых клеток человека
ISKJ
|
2.61 | - | - | - | ||
|
Adverum Biotechnologies
ADVM
|
76.4 | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
25.8 | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
144 | - | -9.65 % | $ 45.9 M | ||
|
Autolus Therapeutics plc
AUTL
|
1.37 K | $ 1.4 | -0.36 % | $ 357 M | ||
|
Exelixis
EXEL
|
5.05 | $ 41.13 | -0.69 % | $ 11.2 B | ||
|
Ayala Pharmaceuticals
AYLA
|
11.2 | - | - | $ 7.46 M | ||
|
ChemoCentryx
CCXI
|
0.0564 | - | - | $ 3.74 B | ||
|
Aytu BioScience
AYTU
|
0.237 | $ 2.63 | - | $ 16.5 M | ||
|
Fulcrum Therapeutics
FULC
|
0.00291 | $ 6.64 | -3.63 % | $ 421 K | ||
|
BioDelivery Sciences International
BDSI
|
1.85 | - | -4.8 % | $ 255 M | ||
|
Genmab A/S
GMAB
|
15.6 | $ 25.59 | -0.35 % | $ 16.5 B | ||
|
Grifols, S.A.
GRFS
|
1.71 | $ 7.64 | -0.72 % | $ 6.83 B | ||
|
Aeglea BioTherapeutics
AGLE
|
489 | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
281 | - | - | $ 867 M | ||
|
BeiGene, Ltd.
BGNE
|
66.4 | - | 0.49 % | $ 251 B | ||
|
Halozyme Therapeutics
HALO
|
6.91 | $ 61.68 | -1.88 % | $ 7.39 B | ||
|
Harmony Biosciences Holdings
HRMY
|
1.85 | $ 26.99 | -2.21 % | $ 1.55 B | ||
|
ImmuCell Corporation
ICCC
|
1.54 | $ 6.43 | 0.31 % | $ 52.5 M | ||
|
Ionis Pharmaceuticals
IONS
|
63.5 | $ 69.48 | -1.85 % | $ 11.1 B | ||
|
Innate Pharma S.A.
IPHA
|
14.7 | $ 1.33 | -2.92 % | $ 235 M | ||
|
Arbutus Biopharma Corporation
ABUS
|
60.1 | $ 4.29 | -2.94 % | $ 822 M | ||
|
AIkido Pharma
AIKI
|
1.08 | - | 1.93 % | $ 17.4 M |